Startseite/Aktien/ALXO

ALXO

USD

ALX Oncology Holdings Inc. Common Stock

$1.460-0.060 (-3.947%)

Echtzeitkurs

Healthcare

Biotechnologie

Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen

Unternehmensfundamentaldaten

Handelsstatistiken

Marktkennzahlen

Eröffnung

$1.520

Hoch

$1.600

Tief

$1.460

Volumen

0.54M

Unternehmensfundamentaldaten

Marktkapitalisierung

78.2M

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

0.93M

Börse

NMS

Währung

USD

52-Wochen-Spanne

Tief $0.404Aktuell $1.460Hoch $2.27

Ähnliche Nachrichten

30. Okt. 2025 · 12:30

GlobeNewswire

ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of

ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting

23. Okt. 2025 · 16:30

GlobeNewswire

ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

-Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors -Robust body of preclinical data supports